modeling-brain-metastasis-via-tail-vein-injection-inflammatory-breast

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells

Metastatic spread to the brain is a common and devastating manifestation of many types of cancer. In the United States alone, about 200,000 patients are ...

The University of Texas MD Anderson Cancer Center

NDRG1 is widely described as a metastasis suppressor in breast cancer. However, we found that NDRG1 is critical in promoting tumorigenesis and brain metastasis in mouse models of inflammatory breast cancer (IBC), a rare but highly aggressive form of breast cancer. We hypothesized that NDRG1 is a prognostic marker associated with poor outcome in patients with IBC. NDRG1 levels in tissue microarrays from 64 IBC patients were evaluated by immunohistochemical staining with NDRG1 (32 NDRG1-low (≤median), 32 NDRG1-high (>median)). Overall and disease-free survival (OS and DSS) were analyzed with Kaplan-Meier curves and log-rank test. Univariate analysis showed NDRG1 expression, tumor grade, disease stage, estrogen receptor (ER) status, and receipt of adjuvant radiation to be associated with OS and DSS. NDRG1-high patients had poorer 10-year OS and DSS than NDRG1-low patients (OS, 19% vs. 45%,  = 0.0278; DSS, 22% vs. 52%,  = 0.0139). On multivariable analysis, NDRG1 independently predicted OS (hazard ratio (HR) = 2.034,  = 0.0274) and DSS (HR = 2.287,  = 0.0174). NDRG1-high ER-negative tumors had worse outcomes OS,  = 0.0003; DSS,  = 0.0003; and NDRG1-high tumors that received adjuvant radiation treatment had poor outcomes (OS,  = 0.0088; DSS,  = 0.0093). NDRG1 was a significant independent prognostic factor for OS and DSS in IBC patients. Targeting NDRG1 may represent a novel strategy for improving clinical outcomes for patients with IBC.

NDRG1 Expression Is an Independent Prognostic Factor in Inflammatory Breast Cancer.

Inflammatory breast cancer (IBC) is a clinically distinct and highly aggressive form of breast cancer with rapid onset and a strong propensity to metastasize. The molecular mechanisms underlying the aggressiveness and metastatic propensity of IBC are largely unknown. Herein, we report that decorin (DCN), a small leucine-rich extracellular matrix proteoglycan, is downregulated in tumors from patients with IBC. Overexpression of DCN in IBC cells markedly decreased migration, invasion, and cancer stem cells in vitro and inhibited tumor growth and metastasis in IBC xenograft mouse models. Mechanistically, DCN functioned as a suppressor of invasion and tumor growth in IBC by destabilizing E-cadherin and inhibiting EGFR/ERK signaling. DCN physically binds E-cadherin in IBC cells and accelerates its degradation through an autophagy-linked lysosomal pathway. We established that DCN inhibits tumorigenesis and metastasis in IBC cells by negatively regulating the E-cadherin/EGFR/ERK axis. Our findings offer a potential therapeutic strategy for IBC, and provide a novel mechanism for IBC pathobiology.

Emilly S. Villodre

Department of Breast Medical Oncology,
Morgan Welch Inflammatory Breast Cancer Clinic and Research Program

The University of Texas MD Anderson Cancer Center

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells

Emilly S. Villodre

.css-o250i3{font-size:18px;font-family:Open Sans,sans-serif;line-height:21.6px;}Department of Breast Medical Oncology,Morgan Welch Inflammatory Breast Cancer Clinic and Research Program

The University of Texas MD Anderson Cancer Center

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells

Department of Breast Medical Oncology,
Morgan Welch Inflammatory Breast Cancer Clinic and Research Program